EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer-Reference-Cited by-同舟云学术

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

Published:2020-02 Issue:2 Volume:156 Page:301-307
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Arend Rebecca C.,Davis Allison M.,Chimiczewski Przemyslaw,O'Malley David M.,Provencher Diane,Vergote Ignace,Ghamande Sharad,Birrer Michael J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference37 articles.

1. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer;Skirnisdottir;Int. J. Cancer,2008

2. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors);Harter;Int. J. Gynecol. Cancer,2014

3. Borderline epithelial tumors of the ovary;Hart;Mod. Pathol.,2005

4. Borderline ovarian tumors: current concepts for prognostic factors and clinical management;Jones;Clin. Obstet. Gynecol.,2006

5. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential;Trimble;Gynecol. Oncol.,2002

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular changes driving low-grade serous ovarian cancer and implications for treatment;International Journal of Gynecologic Cancer;2024-06-30

2. Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers;Cells;2024-06-19

3. Targeting tumour markers in ovarian cancer treatment;Clinica Chimica Acta;2024-06

4. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?;Cancers;2024-05-13

5. A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer;Bioorganic Chemistry;2024-02